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Objectives: To determine whether age-dependent inequalities in care and outcome changed over a 24 year
period for patients admitted with a myocardial infarction (MI).
Methods: We examined four age groups (b55, 55–65, 65–75, and >75 years) and treatment and mortality in
14,434 consecutive patients admitted for MI to an intensive coronary care unit from 1985 to 2008. Temporal
trend analyseswere performed by comparing decades of admission (1985–1990 vs. 1990–2000 vs. 2000–2008).
Results: A total of 2040 (14%) of the patients were >75 years of age. Older patients more often were female and
less often presented with an ST-segment elevation MI (STEMI). Systematic differences in care were present be-
tween the age groups: older patients were less likely to receive evidence-based medical care and reperfusion
therapy during the last 24 years, although the differences became smaller over time. In 2000–2008, 30-day
(adjusted OR 0.28, 95%CI: 0.23–0.34) and 5-year (adjusted HR 0.61, 95%CI: 0.54–0.68) mortality were lower
compared to 1985–1990. These temporal trends were equal across all age groups. Hence, the change in mortal-
ity over the 24-year study period is similar among the spectrum of ages. Patients aged b55, 55–65, 65–75, and
>75 years had a 20-year mortality of 38, 63, 87 and >95%, respectively.
Conclusions: Older patients with an MI remained less likely to receive evidence-based care during 24 years of
observation. Temporal reductions in mortality were similar among all age groups. The application of proven
MI therapies to appropriate patients regardless of age may even further improve these outcomes.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Due to aging of the general population in theWestern world, more
elderly patients present to hospital with a myocardial infarction (MI)
[1]. Previous studies have suggested that elderly patients with an MI
are less likely to receive evidence-based therapies and have a worse
survival after hospitalization compared to younger patients [2–4].
Recent data has underlined the need for increased use of evidence-
based management among the elderly and has shown potential for
a reduction in mortality in this age group [3,5].
Within the past 25 years, substantial improvements in the
treatment and outcome of MI have been made with, for example
the implementation of thrombolytic therapy in the 1990s, primary
percutaneous coronary intervention (PCI) in the beginning of the
new century and tailored treatment according to individual risk
[6–10]. A long-term analysis of patients admitted to hospital with an
MI might identify changes in the use of treatment modalities, and early
and late outcomes for the whole spectrum of ages. Therefore, the aims
of this study were threefold. First, to determine whether, in accordancet of Cardiology, Room Ba-561,
ands. Tel.: +31 10 70 33933;
an Domburg).
Ltd. All rights reserved.with the guideline recommendations [11,12], age-dependent inequal-
ities in care changed over a 24-year period. Second, to compare temporal
trends in mortality according to age for patients admitted with an MI.
And third, to quantify the effect of age on 30-day and long-term
mortality.
2. Methods
We included all consecutive patients aged >18 years admitted for ST-segment el-
evation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction
(NSTEMI) to the Intensive Coronary Care Unit (ICCU) of the Thoraxcenter, Erasmus
University Medical Center between June 1985 and December 2008.
The primary discharge diagnosis of MI was made in the presence of the following
characteristics: chest pain or equivalent symptoms in combination with dynamic ECG
changes consistent with MI and a typical serial rise (to at least three times the upper
normal value) and fall in serum biochemical markers of cardiac necrosis such as
creatine kinase-MB or troponin-T (as of 2002). Patients were diagnosed as STEMI in
the presence of ST-segment elevation >0.1 mV in at least two peripheral leads, or
>0.2 mV in at least two contiguous precordial leads, and as NSTEMI otherwise. For
patients admitted more than once, only the ﬁrst hospitalization was taken into
account.
2.1. Data collection
Trained physicians and nurses accustomed to the use of standardized case report
forms collected the data. Demographic characteristics (age, gender), cardiac history
(previous MI, PCI or coronary artery bypass surgery [CABG]), risk factors (hyperten-
sion, diabetes, family history, smoking status), anemia (hemoglobin levelb13.0 g/dl
Table 1
Baseline characteristics and clinical presentation of patients hospitalized for MI accord-
ing to age on admission.
Age on admission P for
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logical and invasive treatment modalities (thrombolysis and PCI) were collected. The
decision to use or not use speciﬁc pharmacological and invasive treatment modalities
was made according to the level of evidence and recommendations in the guidelines
available at that time.trend
b55 55–65 65–75 >75
No. of patients 4319
(30%)
4113
(29%)
3962
(27%)
2040
(14%)
Baseline
Gender (female) 20% 23% 32% 45% b0.001
Cardiac history2.2. Follow-up and endpoints
The primary endpoint was all cause mortality at 30 days and at 20 years. In-
hospital mortality was retrieved from the medical records. Long-term survival status
was assessed through municipal Civil Registries in 2010 and was available for 99% of
all patients.Previous MI 30% 34% 36% 34% b0.001
Previous PCI 14% 15% 15% 15% 0.37
Previous CABG 7% 10% 12% 10% b0.001
Risk factors
Hypertension 29% 37% 39% 39% b0.001
Diabetes 11% 14% 16% 17% b0.001
Hyperlipidemia 29% 30% 26% 21% b0.001
Family history 35% 29% 21% 14% b0.001
Current smoker 51% 35% 21% 11% b0.001
Renal dysfunction 5% 7% 12% 14% b0.001
Anemia 30% 39% 50% 58% b0.001
Discharge diagnosis
STEMI 54% 47% 41% 45% b0.001
Medication at ICCU
discharge
Ca-antagonist 19% 24% 27% 21% b0.001
Diuretics 8% 11% 16% 20% b0.001
Nitrates 11% 13% 14% 16% b0.001
Antiarrhythmics 4% 4% 4% 4% 0.20
ICCU, intensive coronary care unit.2.3. Statistical analysis
The study patients were categorized into four groups of patients according to age:
those aged b55, 55–65, 65–75, and >75 years. Categorical variables were summarized
as percentages and chi-square test for trend was used to calculate p-values. Patients
were stratiﬁed in three groups according to decade of hospitalization: 1985–1990;
1990–2000; 2000–2008. We assessed temporal trends in outcome by comparing
these three periods. Cumulative survival curves were constructed using the Kaplan–
Meier method for patients aged >75 years. The log-rank test was used to compare sur-
vival curves. We examined the independent association between decade of hospitali-
zation and mortality, for the whole study population and for the elderly, respectively,
using logistic regression for 30-day outcome and the Cox proportional hazards model
for long-term outcome. Since complete long-term (20-year) follow-up of patients ad-
mitted after 1991 is unavailable, we used 5-year outcomes for comparing the inﬂuence
of decades of hospitalization on outcome. Adjustment was performed for gender,
previous MI, previous CABG, hypertension, diabetes, hyperlipidemia, family history,
smoking status, renal dysfunction, anemia and discharge diagnosis. In addition, we
examined the independent association between age and mortality using the analyses
described above.
Results are reported as odds ratios (OR) – for 30-day mortality – and hazard ratios
(HR) – for long-term mortality – and their respective 95% conﬁdence intervals. All sta-
tistical tests were 2-tailed, and p-values were considered signiﬁcant at b0.05. Analysis
was performed using SPSS software version 17.0 (SPSS, Chicago, USA).3. Results
We included 14,434 patients, of whom 2040 (14%) were
>75 years of age. The distribution of age categories is shown in
Table 1. A total of 106,517 person-years were analyzed.3.1. Patient characteristics
Patient characteristics are shown in Table 1. Older patients were
more often female; more often had a history of CABG, anemia and
renal impairment. Older patients were less often current smokers,
less often had hypercholesterolemia, a family history of previous MI,
or a discharge diagnosis of STEMI. For each decade of age, the odds
of presenting with a STEMI decreased by 15% (odds ratio, OR 0.85,
95%CI: 0.83–0.88).3.2. Medical and invasive care during the study period
Age-dependent inequalities in care were present in 1985 and per-
sisted during the 24-year study period. While use of reperfusion ther-
apy (either by thrombolytic therapy or PCI) increased over time in all
groups with STEMI (pb0.001), older patients were less likely to
receive reperfusion therapy (pb0.001), although the differences
appeared to become smaller during the study period (Fig. 1A). Pre-
scription of evidence-based medical care (class 1A), including aspirin,
Β-blockers, and statins was and remained lower in the elderly during
the whole study period (pb0.001 for all). The prescription of ACE-
inhibitors/angiotensin-receptor blockers was lower for older patients
in the 1990s, but not thereafter (Fig. 1B). Prescription of other medi-
cal therapy with a lower level of evidence for the treatment of MI, in-
cluding calcium-antagonists, nitrates and diuretics at ICCU discharge
was higher in the elderly (Table 1).3.3. Temporal trends in mortality
In the total study population, the risk of 30-day mortality de-
creased between 1985 and 2008 from 11% in 1985–90 to 4% in
2000–08. This decrease was more pronounced for patients aged
>75 years, from 27% in 1985–90 to 9% in 2000–08 (Fig. 2A). Also,
for the study population as a whole, 5-year mortality decreased be-
tween 1985 and 2008, from 24% in 1985–90 to 17% in 2000–08, and
for patients aged >75 years from 55% in 1985–90 vs. 40% in 2000–08
(Fig. 2B).
From 1985 to 2008, the adjusted risk of 30-day mortality de-
creased by nearly 75%, in both the overall study population (adjusted
OR 0.28, 95%CI: 0.23–0.34) as well as in the elderly (adjusted OR 0.29,
95%CI: 0.18–0.45; Table 2). The risk of 5-year mortality decreased by
nearly 40% in both the overall study population (adjusted hazard
ratio, HR 0.61, 95%CI: 0.54–0.68) and in the elderly (adjusted HR
0.63, 95%CI: 0.49–0.80; Table 2). Hence, the relative risk reduction
in 30-day and long-term mortality over the 24-year study period
was similar among the spectrum of ages.
3.4. Age and mortality
As expected, the risk of mortality was higher in older MI patients
at 30 days follow-up (13% for patients >75 years vs. 3% for those
b55 years, pb0.001) and during long-term follow-up (Fig. 3: after
16 years, 95% for patients >75 years vs. 29% for those b55 years,
pb0.001). The (adjusted) mortality rates for 30-day and 20-year out-
comes are presented in Table 3. There were no signiﬁcant interactions
between the baseline characteristics and age and mortality. One in
seven of the patients were >75, but one third of the deaths within
30 days occurred in this group.
4. Discussion
In this study conducted in a cohort of 14,434 MI patients, we
showed that systematic differences in care were present between pa-
tients from different age groups: older patients were less likely to
Fig. 1. Treatment of patients over time: use of reperfusion therapy in STEMI (A) and use of evidence-based medical care in MI patients (B). ACE denotes angiotensin-converting
enzyme inhibitor; ASA, aspirin; ARB, angiotensin receptor blocker; ThT, thrombolytic therapy.
Fig. 2. Temporal trends: Kaplan–Meier curves of mortality according to decade of admission in elderly patients (aged >75).
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all 24 years of observation, although the differences became smaller
over time. Furthermore, temporal trends in 30-day and long-term
mortality showed substantial improvements in outcome during this
24-year period that were independent of age. Thus, these improve-
ments in outcome were similar for all age groups. Finally, we demon-
strated the association between age and mortality with follow-up
data up to 20 years.
The better outcomes in younger patients could in part be due to
the fact that effective therapies are better implemented among
these patients. Previous studies [11,13] showed that older patients
with an STEMI who are eligible for reperfusion therapy, actually less
often receive this treatment. Furthermore, other studies [11] showed
that elderly patients with a NSTEMI are substantially less likely to un-
dergo an invasive treatment strategy, while individual trials [14,15]
have suggested that the beneﬁt from an invasive strategy is mainly
observed in patients >65 years of age (the “risk-treatment paradox”).
Other proven therapies are also underused in the elderly [2,16], evenTable 2
Temporal trends of 30-day and 5-year mortality in MI patients.
Calendar period All patients >75
Odds ratios for 30-day mortality
1985–90 Reference Reference
1990–2000 0.61 (0.51–0.74) 0.59 (0.38–0.91)
2000–08 0.28 (0.23–0.34) 0.29 (0.18–0.45)
Hazard ratios for 5-year mortality
1985–90 Reference Reference
1990–2000 0.93 (0.83–1.0) 0.98 (0.77–1.2)
2000–08 0.61 (0.54–0.68) 0.63 (0.49–0.80)
Adjusted for gender, previous MI, previous CABG, hypertension, diabetes, hyperlipidemia,
family history, smoking status, renal dysfunction, anemia and discharge diagnosis.in the absence of contra-indications [17]. These age-related treatment
patterns persisted in the present study, although the overall temporal
increase in the use of evidence-based therapies (especially primary
PCI for STEMI) among the elderly is encouraging and conﬁrms other
recent observations in older patients with STEMI [18].
Thirty-day and long-term mortality after MI have decreased dur-
ing the past decades [10,19]. However, two recent studies suggest
that temporal mortality improvements did not occur in older patients
[20,21]. However, data from our study clearly demonstrates that, in
our center, similar reductions in 30-day and long-term mortality
have occurred across all age groups. In fact, the i) numerically similar
relative reductions over time and ii) the higher absolute mortality in
the elderly, imply that in absolute terms, elderly patients beneﬁted
most from improved medical care during the past 24 years. Still, the
application of evidence-based MI therapies to appropriate patients
regardless of age may even further improve these outcomes.Table 3
Unadjusted and adjusted odds and hazard ratios of mortality according to age at
hospitalization.
Age category Unadjusted Adjusted*
Odds ratios for 30-day mortality
b55 Reference Reference
55–65 1.8 (1.4–2.2) 1.6 (1.3–2.1)
65–75 2.8 (2.3–3.5) 2.5 (2.0–3.1)
>75 5.0 (4.0–6.2) 4.6 (3.6–5.8)
Hazard ratios for 20-year mortality
b55 Reference Reference
55–65 1.9 (1.7–2.1) 1.8 (1.7–2.0)
65–75 3.6 (3.4–4.0) 3.5 (3.2–3.8)
>75 7.3 (6.6–8.0) 7.3 (6.6–8.1)
*Adjusted for the same variables as Table 2 and decade of hospitalization.
Fig. 3. Kaplan–Meier curves of mortality according to age.
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[22]. Relative odds of 6.2 to 7.8 for in-hospital mortality in patients
>75 years compared to b55 years have previously been reported
[3,21,23], ﬁgures similar to those of the present study. Relative
hazards for long-term mortality in the elderly are presented in this
study, with follow-up data comprising almost a whole life course.
4.1. Strengths and limitations
To our knowledge, this is the ﬁrst paper investigating temporal
trends in clinical characteristics, treatment and outcome of older pa-
tients (>75 years) with an MI over a time period of 24 years and
with follow-up data for up to 20 years. Although the present study
has unique strengths, some limitations should be mentioned. First,
the discharge diagnosis of MI was based on the diagnosis of the at-
tending physician. Newer deﬁnitions of MI have been published with-
in the study period; these might interfere with the probability of an
acute coronary syndrome patient to be diagnosed with MI. Still,
these inconsistencies reﬂect clinical practice during these transitional
periods. Second, given the nature of aging this study reveals impor-
tant associations but cannot prove causation. Finally, the present
data are derived from a single center. Although this could result in a
lower external validity, we think that this is unlikely to be the case
since the deﬁnition of myocardial infarction and its therapeutic mo-
dalities are quite uniform, certainly in the Western world.
4.2. Conclusion
The elderly contribute a substantial proportion to MI mortality.
Subjects >75 years of age were less likely to receive evidence-based
medical care and reperfusion therapy over the 24-year study period.
Despite this, improvements in the application of evidence-based MI
care were evident across all age groups from 1985 to 2008. There
were signiﬁcant temporal reductions in 30-day and long-term mor-
tality, that were equal across all age groups. In absolute terms, there-
fore, older patients beneﬁted most from the improved medical care
for MI during the last 24 years. It is likely that a further increase in
the application of evidence-based therapies for MI in the elderly
will further improve their short- and long term outcome.
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